Atlas Antibodies Overview
- Founded
-
2006
- Status
-
Private
- Employees
-
81
- Latest Deal Type
-
2ndary - Private
Atlas Antibodies General Information
Description
Developer of novel antibodies designed to provide advanced research reagents targeting all human proteins. The company's novel antibodies are studied for basic research purposes and clinical research, enabling researchers to know and assist patients to cure of cancer and neurological brain diseases.
Contact Information
Website
www.atlasantibodies.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
- Voltavägen 13A
- 168 69 Bromma
- Sweden
+46 08-545 000 00
Atlas Antibodies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 01-Feb-2021 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 01-Mar-2013 | Completed | Generating Revenue | |||
| 1. Seed Round | 22-Aug-2006 | Completed | Startup |
Atlas Antibodies Patents
Atlas Antibodies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3736574-A1 | A formulation comprising an isotope labeled fusion polypeptide | Inactive | 07-May-2019 | 00000000000 | 0 |
| US-20220042069-A1 | Method for determining levels of interactions between biomolecules | Pending | 09-Feb-2017 | 0000000000 | |
| AU-2018218875-A1 | Method for determining levels of interactions between biomolecules | Pending | 09-Feb-2017 | 0000000000 | |
| CA-3051350-A1 | Method for determining levels of interactions between biomolecules | Pending | 09-Feb-2017 | 0000000000 | |
| EP-3580356-B1 | Method for determining levels of interactions between biomolecules | Active | 09-Feb-2017 | C12Q1/6804 |
Atlas Antibodies Executive Team (16)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Nille Klæbel | Chief Executive Officer | ||
| Martin Skoglund | Chief Financial Officer | ||
| Maria Hjortsmark | Chief Marketing Officer | ||
| Caroline Kampf Ph.D | Chief Scientific Officer | ||
| Maria Faervik | Controller |
Atlas Antibodies Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Else Trautner | Self | Board Member | 000 0000 |
| Lennart Johansson | Atlas Antibodies | Board Member | 000 0000 |
| Lotta Ljungqvist Ph.D | Self | Board Member | 000 0000 |
| Mathias Uhlén Ph.D | Atlas Antibodies | Co-Founder & Board Member | 000 0000 |
| Torben Jørgensen | Self | Chairman | 000 0000 |
Atlas Antibodies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Atlas Antibodies Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 05-Aug-2021 | 0000000000 | Biotechnology | 000000 0ø | |
| 000000000 000 | 16-Feb-2021 | 0000000000 | Drug Discovery | 0000 0000 | |
| Alligator Bioscience | 29-May-2007 | Later Stage VC | 00.000 | Drug Discovery | 0000000 0 |
Atlas Antibodies Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| HistoCyte Laboratories | Drug Discovery | Newcastle upon Tyne, United Kingdom | 2014 |
| 0000000 | Biotechnology | Schlieren, Switzerland | 0000 |
Atlas Antibodies Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000 00000000 | 29-May-2007 | 00000 00000 00 | 00.000 | Completed |
|